DRUG
oxytocin
Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
Status
Unknown
Phase
Not applicable
Enrollment
260
Locations
1
Results
Not posted
Publications
1
Study summary
As both oxytocin and carbetocin are used daily in obstetric units all over the world, the investigators find it compelling to investigate whether the hemodynamic and myocardial effects of oxytocin and carbetocin are comparable in healthy women during delivery and determine any potential harmful effects following the use of oxytocin or Carbetocin as uterotonic. Other endpoints relating to uterus tone, blood loss, blood pressure, heart rate, post-operative pain and side effects will also be assessed.
Although the difference between carbetocin and oxytocin in terms of hemodynamic changes, postpartum blood loss and incidence of side effects is not statistically significant. serious cardiovascular adverse events, including ST segment depression, hypotension and tachycardia have been reported after IV oxytocin. Oxytocin dose reduction and/or increased infusion duration may reduce risk of some cardiac-related adverse effects and increase patient safety. As both oxytocin and carbetocin are used daily in obstetric units all over the world, the investigators find it compelling to investigate whether the hemodynamic and myocardial effects of oxytocin and carbetocin are comparable in healthy women during delivery and determine any potential harmful effects following the use of oxytocin or Carbetocin as uterotonic. Other endpoints relating to uterus tone, blood loss, blood pressure, heart rate, post-operative pain and side effects will also be assessed.
Interventions
DRUG
Participants will be randomized to receive Oxytocin after delivery of the baby's head and shoulders
DRUG
Participants will be randomized to receive Cabetocin after delivery of the baby's head and shoulders
Timeline
First posted
Mar 7, 2023
Study start
May 1, 2023
Primary completion
Nov 1, 2024
Study completion
Dec 1, 2024
Results posted
Not reported
Registry updated
Mar 7, 2023
Outcomes
Myocardial effects
Time frame · immediately before drug administration
Electrocardiograph (QT interval)
Myocardial effects
Time frame · 24 hours after drug administration
Electrocardiograph (QT interval)
Cardiac enzyme
Time frame · immediately before drug administration
Troponin
Cardiac enzyme
Time frame · 24 hours after drug administration
Troponin
Uterine contraction
Time frame · One hour post delivery
Palpate the fundus throughout a contraction to determine intensity
Eligibility
Inclusion Criteria: * Normal singleton pregnancy at gestational age of 36 weeks or more. * Women with common comorbid diagnoses (diabetes, hypothyroidism, hypertension) * pregnancy after in vitro fertilization Exclusion Criteria: * placenta praevia or invasive placenta. * pre-eclampsia. * Bleeding disorder, such as von Willebrand disease type I. * Current treatment with low-molecular-weight heparin or other anticoagulation medication (not including aspirin). * Any known intolerance to either of the study drugs. * Prolonged QT-time. * Other serious cardiac disease. * Liver or kidney failure.
Study locations
Kuwait. Showing up to 24 locations stored in the fast local snapshot.
Munistery of Health Kuwait
Kuwait City, Kuwait
Publications
Related trials
Alex Ekwueme Federal University Teaching Hospital · Blood Loss, Surgical
Early Phase 1
Not yet recruiting
900
2026-07
Mansoura University · Postpartum Hemorrhage · Uterine Atony
Phase 4
Not yet recruiting
332
2026-06
Sheba Medical Center · Postpartum Hemorrhage · Twin Pregnancy
Phase 4
Recruiting
120
2026-05
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Postpartum Hemorrhage
Not applicable
Recruiting
32
2026-04
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Post Partum Hemorrhage
Not applicable
Recruiting
160
2026-04
Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Postpartum Hemorrhage (Primary)
Not applicable
Recruiting
120
2026-04
Ankara Etlik City Hospital · Postpartum Hemorrhage \(PPH\)
Not applicable
Completed
300
2026-02
Oslo University Hospital · Pregnancy Complications
Phase 4
Completed
240
2026-02
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.